Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Int J Chron Obstruct Pulmon Dis. 2014 Dec 12;9:1389-96. doi: 10.2147/COPD.S49519. eCollection 2014.
Regenerative or stem cell therapy is an emerging field of treatment based on stimulation of endogenous resident stem cells or administration of exogenous stem cells to treat diseases or injury and to replace malfunctioning or damaged tissues. Current evidence suggests that in the lung, these cells may participate in tissue homeostasis and regeneration after injury. Animal and human studies have demonstrated that tissue-specific stem cells and bone marrow-derived cells contribute to lung tissue regeneration and protection, and thus administration of exogenous stem/progenitor cells or humoral factors responsible for the activation of endogenous stem/progenitor cells may be a potent next-generation therapy for chronic obstructive pulmonary disease. The use of bone marrow-derived stem cells could allow repairing and regenerate the damaged tissue present in chronic obstructive pulmonary disease by means of their engraftment into the lung. Another approach could be the stimulation of resident stem cells by means of humoral factors or photobiostimulation.
再生或干细胞治疗是一种新兴的治疗方法,基于刺激内源性驻留干细胞或给予外源性干细胞,以治疗疾病或损伤,并替代功能失调或受损的组织。目前的证据表明,在肺部,这些细胞可能参与损伤后的组织稳态和再生。动物和人体研究表明,组织特异性干细胞和骨髓来源的细胞有助于肺组织再生和保护,因此给予外源性干细胞/祖细胞或负责激活内源性干细胞/祖细胞的体液因子可能是一种治疗慢性阻塞性肺疾病的下一代有效方法。骨髓来源的干细胞的使用可以通过其在肺中的植入来修复和再生慢性阻塞性肺疾病中存在的受损组织。另一种方法可能是通过体液因子或光生物刺激来刺激驻留干细胞。